Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Omnia TeleHealth vs REMEVi

Omnia TeleHealth
Graded #418

Lower grade

vs+17.299999999999997
REMEVi
Graded #70

Higher grade

The verdict

REMEVi takes it — 73.5/100 to 56.2/100.

REMEVi grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. REMEVi is the first bilingual (English and Spanish) GLP-1 telehealth clinic — care delivered by clinicians trained in both languages, never auto-translated.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueREMEVi +12
45
57
Dose & formulationREMEVi +43
40
83
Clinical oversightREMEVi +6
80
86
Labs & monitoringOmnia TeleHealth +6
61
55
FulfillmentREMEVi +35
62
97
Contract termsREMEVi +14
55
69
Omnia TeleHealth · left barREMEVi · right bar

The numbers

MetricOmnia TeleHealthREMEVi
WeighScore56.2/10073.5/100
GradeCC
Scorecard rank#418#70
SemaglutideNot disclosed$219/mo
TirzepatideNot disclosed$319/mo
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
Omnia TeleHealth

Graded #418 · C

Strengths

  • LegitScript-certified; DNP-led by Blair Carmichael-Lober with 10+ years clinical experience
  • $69 flat consult fee — no insurance, no surprise bills; works with Belmar Pharma for compounded GLP-1
  • Both semaglutide and tirzepatide available; compounded options via Belmar at lower cost than brand
  • Weight loss visits include nutrition guidance, exercise recommendations, and behavioral coaching
  • Prescriptions sent to any pharmacy nationwide or coordinated through Belmar Pharma Solutions

Where it loses points

  • Only 17 states — specific states not publicly disclosed; must call (251) 220-8875 to confirm
  • Medication pricing is gated — not published on website; contact required for compounded GLP-1 cost
  • No labs mentioned or included — baseline bloodwork protocol not published on any page
  • Medication cost is a separate pharmacy bill; the $69 visit fee covers consult only
  • Smaller platform with limited public track record vs. larger national GLP-1 telehealth providers
REMEVi

Graded #70 · C

Strengths

  • A genuinely flat rate: 'the same price at every dose', stated as such, with no dose upcharge and no introductory rate to step off
  • Longer terms are published openly rather than used as a teaser — semaglutide falls to $189 on 12 weeks and $149 on 52
  • A daily oral semaglutide tablet is offered alongside the injection
  • Available in all 50 states and DC, with no minimum commitment and no cancellation fee

Where it loses points

  • The flat rate is the highest entry price of the top-scoring programmes here; the cheaper $149 figure needs a full year
  • No FDA-approved brand-name pathway — the Wegovy and Ozempic pages are comparison content, not products
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard